ClinicalTrials.gg
CompletedNCT00071747Updated Sep 1, 2016

Clinical Study Of Schizophrenia in Both Men and Women

A Phase 3 interventional study of lamotrigine in Schizophrenia, sponsored by GlaxoSmithKline. Completed at 32 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-09-01.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Schizophrenia by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Schizophrenia · GlaxoSmithKline.

Enrollment
6th of 22
176 · median 46
Started
2003
the only one that year
Phase 3
2 of 23
none open now
Registered
2nd of 23
by date

Among the 23 studies in Schizophrenia by GlaxoSmithKline, this one is the 6th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2003, is one of 2 in phase 3, and was the 2nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 23 studies in Schizophrenia by GlaxoSmithKline is open now. The open studies under Schizophrenia, anywhere →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies in Schizophrenia by GlaxoSmithKline as a file.
02

Study summary

The objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects with schizophrenia who have been maintained on a stable dose of antipsychotics and who fulfill the screening entrance criteria will have an assessment 1-7 days after the first visit to confirm eligibility.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • schizophrenia
  • lamotrigine
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception.
  • Diagnosis of Schizophrenia
  • Patients must be taking clozapine monotherapy or other atypical antipsychotic at least 3 months prior to this study.

Exclusion criteria

Exclusion criteria:

  • Patients who are currently taking or have taken antidepressant medication in the last month prior.
  • Patients who are or have been suicidal or homicidal in the last 6 months.
  • Patients with a history of autistic disorder or another pervasive developmental disorder
  • Patients whose condition is due to the direct physiological effects of a substance (e.g. a drug of abuse, a medication) or a general medical condition
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
176 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in the total score of the 7 items of the Positive and Negative Symptom Scale (PANSS) positive symptom subscale for lamotrigine vs. placebo at Week 12.

    Time frame: 12 Weeks

Secondary outcomes

  1. Change from baseline in the PANSS total score at Week 12; Change from baseline in the Scale for the Assessment of Negative Symptoms (SANS) at Week 12; Change from baseline in the Clinical Global Impression-Severity of Illness (CGI-S) score at Week 12.

    Time frame: 12 Weeks

07

Study locations

32 sites
  • GSK Investigational Site
    Little Rock, Arkansas 72201, United States
  • GSK Investigational Site
    Garden Grove, California 92845, United States
  • GSK Investigational Site
    La Mesa, California 91942, United States
  • GSK Investigational Site
    National City, California 91950, United States
  • GSK Investigational Site
    Oceanside, California 92056, United States
  • GSK Investigational Site
    Rosemead, California 91770, United States
  • GSK Investigational Site
    San Diego, California 92126, United States
  • GSK Investigational Site
    Hartford, Connecticut 06106, United States
  • GSK Investigational Site
    Maitland, Florida 32751, United States
  • GSK Investigational Site
    North Miami, Florida 33161, United States
  • GSK Investigational Site
    Granite City, Illinois 62040, United States
  • GSK Investigational Site
    Glen Burnie, Maryland 21061, United States
  • GSK Investigational Site
    Rockville, Maryland 20852, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Reno, Nevada 89512, United States
  • GSK Investigational Site
    Clementon, New Jersey 08021, United States
  • GSK Investigational Site
    Kenilworth, New Jersey 07033, United States
  • GSK Investigational Site
    Orangeburg, New York 10962, United States
  • GSK Investigational Site
    Rochester, New York 14620, United States
  • GSK Investigational Site
    Butner, North Carolina 27509, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28211, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27603, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27609, United States
  • GSK Investigational Site
    Beachwood, Ohio 44122, United States
  • GSK Investigational Site
    Cleveland, Ohio 44106, United States
  • GSK Investigational Site
    Lyndhurst, Ohio 44124, United States
  • GSK Investigational Site
    Norristown, Pennsylvania 19401, United States
  • GSK Investigational Site
    Austin, Texas 78756, United States
  • GSK Investigational Site
    Bellaire, Texas 77401, United States
  • GSK Investigational Site
    DeSoto, Texas 75115, United States
  • GSK Investigational Site
    Midvale, Utah 84047, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Publications

  • Goff DC, Keefe R, Citrome L, Davy K, Krystal JH, Large C, Thompson TR, Volavka J, Webster EL. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol. 2007 Dec;27(6):582-9. doi: 10.1097/jcp.0b013e31815abf34. PubMed 18004124 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2003
First posted
Oct 31, 2003
Start
Aug 2003
CompletionActual
Jan 2005
Last update
Sep 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00071747
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 31, 2003
Start date
Aug 2003
Completion
Jan 2005
Last update
Sep 1, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion